Advertisement

Time Series Analysis of California’s Prescription Monitoring Program: Impact on Prescribing and Multiple Provider Episodes

Published:November 24, 2011DOI:https://doi.org/10.1016/j.jpain.2011.09.006

      Abstract

      Prescription monitoring programs (PMPs) are designed to reduce medication diversion by identifying individuals obtaining the same medication from multiple providers (termed multiple provider episodes [MPEs]). This study determined whether recent changes to California’s PMP influenced: 1) the extent that practitioners issue prescriptions for a variety of Schedule II opioids; and 2) the incidence of MPEs involving these opioids. Intervention time series of California’s PMP data was used to determine the effect of requiring practitioners to transition from using triplicate prescription forms for Schedule II medications to security forms for all controlled substances. Outcome measures included changes in number of prescriptions issued for Schedule II long-acting or short-acting (SA) opioids and the MPEs involving these medications. Requiring a security form was associated with a sustained prescribing increase for SA hydromorphone, meperidine, and SA oxycodone; no prescribing changes were found for SA fentanyl, methadone, and SA morphine, or for any long-acting opioids. The same policy change, however, increased MPEs involving all opioids. Further effort is required to determine how California’s PMP can continue to ensure availability of prescription opioids for medical use while better mitigating their diversion.

      Perspective

      Statistical model-building was used to evaluate the influence of changes to California’s prescription monitoring program. The extent that practitioners prescribe Schedule II opioids and the incidence of people receiving prescriptions from multiple providers were measured. Such research illustrates the viability of evaluating drug control program impact on prescribing practice and potential diversion behaviors.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Pain Society
        Principles of analgesic use in the treatment of acute pain and cancer pain. Sixth.
        American Pain Society, Glenview, IL2008
        • Ballantyne J.C.
        • LaForge K.S.
        Opioid dependence and addiction during opioid treatment of chronic pain.
        Pain. 2007; 129: 235-255
        • Box G.E.P.
        • Jenkins G.M.
        • Reinsel G.C.
        Time series analysis: Forecasting and control. 3.
        Prentice Hall, Upper Saddle River, NJ1994
        • Brushwood D.B.
        Maximizing the value of electronic prescription monitoring programs.
        J Law Med Ethics. 2003; 31: 41-54
        • Curtis L.H.
        • Stoddard J.
        • Radeva J.I.
        • Hutchison S.
        • Dans P.E.
        • Wright A.
        • Woosley R.L.
        • Schulman K.A.
        Geographic variation in the prescription of Schedule II opioid analgesics amoung outpatients in the United States.
        Health Serv Res. 2006; 41: 837-855
      1. Drug Enforcement Administration: Q & A State prescription drug monitoring programs. 2010. http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm. Accessed November 14, 2011

        • Fishbain D.A.
        • Cole B.
        • Lewis J.
        • Rosomoff H.L.
        • Rosomoff R.S.
        What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.
        Pain Med. 2008; 9: 444-459
        • Fishman S.M.
        • Papazian J.S.
        • Riches P.S.
        • Gilson A.M.
        Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain.
        Pain Med. 2004; 5: 309-324
        • Gilson A.M.
        Laws and policies involving pain management.
        in: Ballantyne J.C. Rathmell J.P. Fishman S.M. Bonica’s Management of Pain. Lippincott Williams & Wilkins, Hagerstown, MD2010
        • Gilson A.M.
        • Kreis P.G.
        The burden of the nonmedical use of prescription opioid analgesics.
        Pain Med. 2010; 10: 89-100
        • Glass G.V.
        • Willson V.L.
        • Gottman J.M.
        Design and analysis of time-series experiments.
        Information Age Publishing, Charlotte, NC2008
        • Joranson D.E.
        • Carrow G.M.
        • Ryan K.M.
        • Schaefer L.
        • Gilson A.M.
        • Good P.
        • Eadie J.
        • Peine S.
        • Dahl J.L.
        Pain management and prescription monitoring.
        J Pain Symptom Manage. 2002; 23: 231-238
        • Joranson D.E.
        • Ryan K.M.
        • Gilson A.M.
        • Dahl J.L.
        Trends in medical use and abuse of opioid analgesics.
        JAMA. 2000; 283: 1710-1714
        • Katz N.
        • Panas L.
        • Kim M.
        • Auder A.D.
        • Bilansky A.
        • Eadie J.
        • Kreiner P.
        • Paillard F.C.
        • Thomas C.
        • Carrrow G.
        Usefulness of prescription monitoring programs for surveillance: Analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006.
        Pharmacoepidemiol Drug Saf. 2010; 19: 115-123
        • Lineberry T.W.
        • Bostwick M.
        Taking the physician out of “physician shopping”: A case series of clinical problems associated with internet purchases of medication.
        Mayo Clin Proc. 2004; 79: 1031-1034
        • McDowall D.
        • McCleary R.
        • Meidinger E.E.
        • Hay Jr., R.A.
        Interrupted time series analysis.
        Sage Publications, Beverly Hills, CA1980
      2. Medical Board of California: Clarification of Senate Bill 151, 2004

      3. Office of National Drug Control Policy: National drug control strategy. NCJ 203722. The White House, 2004

      4. Pain & Policy Studies Group: Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation.
        Fifth edition. University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI2008
        • Pradel V.
        • Frauger E.
        • Thirion X.
        • Ronfle E.
        • Lapierre V.
        • Masut A.
        • Coudert C.
        • Blin O.
        • Micallef J.
        Impact of prescription monitoring program on doctor-shopping for high dosage buprenorphine.
        Pharmacoepidemiol Drug Saf. 2009; 18: 36-43
        • Red Book
        RED BOOK Ambulatory Care Drug Database Coding System.
        Reuters Thompson, Ann Arbor, MI2006
        • Reidenberg M.M.
        Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State.
        Clin Pharmacol Ther. 1991; 50: 129-131
        • Reisman R.M.
        • Shenoy P.J.
        • Atherly A.J.
        • Flowers C.R.
        Prescription opioid usage and abuse relationships: An evaluation of state prescription drug monitoring program efficacy.
        Subst Abuse. 2009; 3: 41-51
        • Ross-Degnan D.
        • Simoni-Wastila L.
        • Brown J.S.
        • Mah M.
        • Cosler L.E.
        A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a medicaid population.
        Int J Psychiatry Med. 2004; 34: 103-123
        • Sigler K.A.
        • Guernsey B.G.
        • Ingrim N.B.
        • Buesing A.S.
        • Hokanson J.A.
        • Galvan E.
        • Doutre W.H.
        Effect of a triplicate prescription law on prescribing of Schedule II drugs.
        Am J Hosp Pharm. 1984; 41: 108-111
        • Simoni-Wastila L.
        • Ross-Degnan D.
        • Mah C.
        • Gao X.
        • Brown J.
        • Cosler L.E.
        • Fanning T.
        • Gallagher P.
        • Salzman G.
        A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders.
        Clin Ther. 2004; 26: 322-336
      5. United States General Accounting Office: Prescription drugs: State monitoring programs provide useful tool to reduce diversion. Washington, DC: United States General Accounting Office, GAO-02-634, 2002

        • Van Haaren A.M.
        • Lapane K.L.
        • Hughes C.M.
        Effect of triplicate prescription policy on benzodiazepine administration in nursing home residents.
        Pharmacotherapy. 2001; 21: 1159-1166
        • Wagner A.K.
        • Soumerai S.B.
        • Zhang F.
        • Mah C.
        • Simoni-Wastila L.
        • Cosler L.E.
        • Fanning T.
        • Gallagher P.
        • Ross-Degnan D.
        Effects of state surveillance on new post-hospitalization benzodiazepine use.
        Int J Qual Health Care. 2003; 15: 423-431
        • Wastila L.J.
        • Bishop C.
        The influence of multiple copy prescription programs on analgesic utilization.
        J Pharm Care Pain Symptom Control. 1996; 4: 3-19
        • Weintraub M.
        • Singh S.
        • Byrne L.
        • Maharaj K.
        • Guttmacher L.
        Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations.
        JAMA. 1991; 266: 2392-2397
        • Wilsey B.L.
        • Fishman S.M.
        • Gilson A.M.
        • Casamalhuapa C.
        • Baxi H.
        • Zhang H.
        • Li C.S.
        Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics.
        Drug Alcohol Depend. 2010; 112: 99-106
        • Zullich S.G.
        • Grasela Jr., T.H.
        • Fiedler-Kelly J.B.
        • Gengo F.M.
        Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities.
        Ann Pharmacother. 1992; 26: 539-546